CRISPR 101

August 29, 2019

Although CRISPR has now become synonymous with gene editing, it is not the first technology developed to edit DNA. 

Spotlight

PharmaSynth

PharmaSynth Pty Ltd is one of Australia’s most experienced biopharmaceutical contract manufacturing organisations. PharmaSynth is conveniently located in Brisbane, Queensland. We offer an inclusive set of services including GMP manufacture of recombinant proteins, vaccines and synthetic molecules for human and veterinary use. We can produce GMP material for pre-clinical studies and clinical trial material batches for Phase 1, 2 and 3 clinical studies.

OTHER WHITEPAPERS
news image

Biopharmaceutical Sector

whitePaper | May 29, 2023

tronger than expected US inflation and a bump in consumer spending have fuelled worldwide expectations that interest rates will go higher, as predictions about future monetary policy rapidly shift.

Read More
news image

Leveraging innovations in plasmid manufacturing to bring advanced therapies to market

whitePaper | December 13, 2022

The global demand for plasmid DNA has increased dramatically in recent years, fueled by a surge in the clinical development of next-generation cell and gene therapy products and more recently by the success of COVID-19 vaccines.

Read More
news image

Bold Goals for U.S. Biotechnology and Biomanufacturing

whitePaper | March 22, 2023

The world is on the cusp of an industrial revolution fueled by biotechnology and biomanufacturing. Emerging biological technologies are and will continue to transform the foundation of our physical world – everything from clothing, to plastics, to fuels, to concrete.

Read More
news image

Accelerating the Biomanufacturing Revolution

whitePaper | February 11, 2022

The biomanufacturing revolution is here. Recent advancements in the field of synthetic biology have enabled significant cost reductions in foundational bioengineering unit operations such as DNA synthesis and sequencing.

Read More
news image

Vaccine and Biologics Development in an Emerging Post Pandemic Landscape

whitePaper | September 20, 2022

It is clear within the global health science industry that analytical biosafety testing and advances in developing scientific technologies will play an important role in drug development’s response to the next pandemic.

Read More
news image

Establishment of the basidiomycete Fomes fomentarius for the production of composite materials

whitePaper | February 24, 2022

Filamentous fungi of the phylum Basidiomycota are considered as an attractive source for the biotech‑ nological production of composite materials. The ability of many basidiomycetes to accept residual lignocellulosic plant biomass from agriculture and forestry.

Read More

Spotlight

PharmaSynth

PharmaSynth Pty Ltd is one of Australia’s most experienced biopharmaceutical contract manufacturing organisations. PharmaSynth is conveniently located in Brisbane, Queensland. We offer an inclusive set of services including GMP manufacture of recombinant proteins, vaccines and synthetic molecules for human and veterinary use. We can produce GMP material for pre-clinical studies and clinical trial material batches for Phase 1, 2 and 3 clinical studies.

Events